New data presented at the American Society of Retina Specialists 2024 examine the benefits and adverse event profiles of two therapies recently approved to treat dry age-related macular degeneration ...

Please provide your email address to receive an email when new articles are posted on . SEATTLE — At the American Society of Retina Specialists annual meeting, the ReST Committee shared an update on ...

Advances in neovascular macular degeneration, as presented at the American Society of Retina Specialists (ASRS) 2025 annual meeting, include data on efficacy and dosing intervals for aflibercept 8 mg ...

About ANX007 and Phase 2 ARCHER TrialANX007 is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical ...

Apellis Pharmaceuticals' Syfovre, after achieving the first FDA approval for advanced eye disease geographic atrophy, has been associated with rare but severe side effects, according to the American ...

In this video, Barbara Blodi, MD, discusses advancements in gene therapy for the treatment of age-related macular degeneration. At the ASRS annual meeting, several sessions revolved around gene ...

Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results ...